$ICPT Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in INTERCEPT PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in INTERCEPT PHARMACEUTICALS, INC.. Get notifications about new insider transactions in INTERCEPT PHARMACEUTICALS, INC. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 01 2021 | ICPT | INTERCEPT PHARMACE ... | BRADBURY DANIEL | Director | Option Exercise | A | 17.08 | 12,089 | 206,480 | 12,089 | |
| Jun 01 2021 | ICPT | INTERCEPT PHARMACE ... | BRADBURY DANIEL | Director | Grant | A | 0.00 | 7,029 | 0 | 15,811 | 8.8 K to 15.8 K (+80.04 %) |
| Jun 01 2021 | ICPT | INTERCEPT PHARMACE ... | SBLENDORIO GLENN | Director | Option Exercise | A | 17.08 | 12,089 | 206,480 | 12,089 | |
| Jun 01 2021 | ICPT | INTERCEPT PHARMACE ... | SBLENDORIO GLENN | Director | Grant | A | 0.00 | 7,029 | 0 | 15,710 | 8.7 K to 15.7 K (+80.97 %) |
| May 13 2021 | ICPT | INTERCEPT PHARMACE ... | Cawkwell Gail | SVP, Med Affairs, S ... | Payment of Exercise | F | 17.75 | 319 | 5,662 | 32,553 | 32.9 K to 32.6 K (-0.97 %) |
| May 11 2021 | ICPT | INTERCEPT PHARMACE ... | Ford David A | Chief Human Resourc ... | Payment of Exercise | F | 17.15 | 128 | 2,195 | 23,711 | 23.8 K to 23.7 K (-0.54 %) |
| May 04 2021 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | Director | Payment of Exercise | F | 19.78 | 3,817 | 75,500 | 502,649 | 506.5 K to 502.6 K (-0.75 %) |
| May 04 2021 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | Director | Grant | A | 19.78 | 6,138 | 121,410 | 506,466 | 500.3 K to 506.5 K (+1.23 %) |
| Apr 05 2021 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 24.28 | 46 | 1,117 | 27,341 | 27.4 K to 27.3 K (-0.17 %) |
| Apr 05 2021 | ICPT | INTERCEPT PHARMACE ... | Venezia Rocco | Chief Accounting Of ... | Payment of Exercise | F | 24.28 | 29 | 704 | 14,289 | 14.3 K to 14.3 K (-0.20 %) |
| Apr 05 2021 | ICPT | INTERCEPT PHARMACE ... | Ford David A | Chief Human Resourc ... | Payment of Exercise | F | 24.28 | 92 | 2,234 | 23,839 | 23.9 K to 23.8 K (-0.38 %) |
| Apr 05 2021 | ICPT | INTERCEPT PHARMACE ... | Durso Jerome Benedict | President & CEO | Payment of Exercise | F | 24.28 | 289 | 7,017 | 82,142 | 82.4 K to 82.1 K (-0.35 %) |
| Apr 01 2021 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | Director | Payment of Exercise | F | 23.08 | 3,658 | 84,427 | 500,328 | 504 K to 500.3 K (-0.73 %) |
| Apr 01 2021 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | Director | Grant | A | 23.08 | 6,136 | 141,619 | 503,986 | 497.9 K to 504 K (+1.23 %) |
| Mar 12 2021 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Buy | P | 21.29 | 147,000 | 3,129,630 | 640,688 | 493.7 K to 640.7 K (+29.78 %) |
| Mar 12 2021 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Buy | P | 21.55 | 16,559 | 356,846 | 493,688 | 477.1 K to 493.7 K (+3.47 %) |
| Mar 12 2021 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Buy | P | 20.83 | 73,441 | 1,529,776 | 477,129 | 403.7 K to 477.1 K (+18.19 %) |
| Feb 25 2021 | ICPT | INTERCEPT PHARMACE ... | Durso Jerome Benedict | President & CEO | Payment of Exercise | F | 28.12 | 319 | 8,970 | 82,431 | 82.8 K to 82.4 K (-0.39 %) |
| Feb 17 2021 | ICPT | INTERCEPT PHARMACE ... | Richardson Linda M | EVP & Chief Commerc ... | Option Exercise | A | 31.32 | 8,500 | 266,220 | 8,500 | |
| Feb 17 2021 | ICPT | INTERCEPT PHARMACE ... | Richardson Linda M | EVP & Chief Commerc ... | Grant | A | 0.00 | 5,531 | 0 | 26,866 | 21.3 K to 26.9 K (+25.92 %) |
| Feb 17 2021 | ICPT | INTERCEPT PHARMACE ... | Cawkwell Gail | SVP, Med Affairs, S ... | Payment of Exercise | F | 31.32 | 319 | 9,991 | 32,872 | 33.2 K to 32.9 K (-0.96 %) |
| Feb 10 2021 | ICPT | INTERCEPT PHARMACE ... | Ford David A | Chief Human Resourc ... | Payment of Exercise | F | 36.04 | 148 | 5,334 | 23,931 | 24.1 K to 23.9 K (-0.61 %) |
| Feb 02 2021 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | Director | Payment of Exercise | F | 35.24 | 2,741 | 96,593 | 494,453 | 497.2 K to 494.5 K (-0.55 %) |
| Feb 02 2021 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | Director | Grant | A | 35.24 | 6,138 | 216,303 | 497,194 | 491.1 K to 497.2 K (+1.25 %) |
| Feb 01 2021 | ICPT | INTERCEPT PHARMACE ... | Freedberg Jared | General Counsel and ... | Option Exercise | A | 36.90 | 69,400 | 2,560,860 | 69,400 | |
| Feb 01 2021 | ICPT | INTERCEPT PHARMACE ... | Freedberg Jared | General Counsel and ... | Grant | A | 0.00 | 44,277 | 0 | 44,277 | 0 to 44.3 K |
| Jan 26 2021 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Option Exercise | A | 29.46 | 19,700 | 580,362 | 19,700 | |
| Jan 26 2021 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Grant | A | 0.00 | 12,600 | 0 | 27,744 | 15.1 K to 27.7 K (+83.20 %) |
| Jan 26 2021 | ICPT | INTERCEPT PHARMACE ... | Kapadia Sandip | CFO and Treasurer | Option Exercise | A | 29.46 | 26,900 | 792,474 | 26,900 | |
| Jan 26 2021 | ICPT | INTERCEPT PHARMACE ... | Kapadia Sandip | CFO and Treasurer | Grant | A | 0.00 | 17,200 | 0 | 40,964 | 23.8 K to 41 K (+72.38 %) |
| Jan 26 2021 | ICPT | INTERCEPT PHARMACE ... | Ford David A | Chief Human Resourc ... | Option Exercise | A | 29.46 | 18,000 | 530,280 | 18,000 | |
| Jan 26 2021 | ICPT | INTERCEPT PHARMACE ... | Ford David A | Chief Human Resourc ... | Grant | A | 0.00 | 11,500 | 0 | 24,079 | 12.6 K to 24.1 K (+91.42 %) |
| Jan 26 2021 | ICPT | INTERCEPT PHARMACE ... | Campagna Jason | Chief Medical Offic ... | Option Exercise | A | 29.46 | 19,700 | 580,362 | 19,700 | |
| Jan 26 2021 | ICPT | INTERCEPT PHARMACE ... | Campagna Jason | Chief Medical Offic ... | Grant | A | 0.00 | 12,600 | 0 | 20,531 | 7.9 K to 20.5 K (+158.87 %) |
| Jan 26 2021 | ICPT | INTERCEPT PHARMACE ... | Durso Jerome Benedict | President & CEO | Option Exercise | A | 29.46 | 72,000 | 2,121,120 | 72,000 | |
| Jan 26 2021 | ICPT | INTERCEPT PHARMACE ... | Durso Jerome Benedict | President & CEO | Grant | A | 0.00 | 46,000 | 0 | 82,750 | 36.8 K to 82.8 K (+125.17 %) |
| Jan 26 2021 | ICPT | INTERCEPT PHARMACE ... | Cawkwell Gail | SVP, Med Affairs, S ... | Option Exercise | A | 29.46 | 19,700 | 580,362 | 19,700 | |
| Jan 26 2021 | ICPT | INTERCEPT PHARMACE ... | Cawkwell Gail | SVP, Med Affairs, S ... | Grant | A | 0.00 | 12,600 | 0 | 33,191 | 20.6 K to 33.2 K (+61.19 %) |
| Jan 11 2021 | ICPT | INTERCEPT PHARMACE ... | BALL BRYAN | Chief Quality Offic ... | Option Exercise | A | 31.26 | 39,185 | 1,224,923 | 39,185 | |
| Jan 11 2021 | ICPT | INTERCEPT PHARMACE ... | BALL BRYAN | Chief Quality Offic ... | Grant | A | 0.00 | 25,000 | 0 | 25,000 | 0 to 25 K |
| Dec 16 2020 | ICPT | INTERCEPT PHARMACE ... | Kapadia Sandip | CFO and Treasurer | Sell | S | 32.78 | 1,763 | 57,791 | 27,158 | 28.9 K to 27.2 K (-6.10 %) |
| Nov 30 2020 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 37.27 | 357 | 13,305 | 15,977 | 16.3 K to 16 K (-2.19 %) |
| Nov 16 2020 | ICPT | INTERCEPT PHARMACE ... | Sullivan Ryan T | General Counsel and ... | Payment of Exercise | F | 37.87 | 493 | 18,670 | 24,708 | 25.2 K to 24.7 K (-1.96 %) |
| Nov 16 2020 | ICPT | INTERCEPT PHARMACE ... | Cawkwell Gail | SVP, Med Affairs, S ... | Payment of Exercise | F | 38.52 | 319 | 12,288 | 21,297 | 21.6 K to 21.3 K (-1.48 %) |
| Nov 10 2020 | ICPT | INTERCEPT PHARMACE ... | Ford David A | Chief Human Resourc ... | Payment of Exercise | F | 28.15 | 128 | 3,603 | 13,314 | 13.4 K to 13.3 K (-0.95 %) |
| Oct 05 2020 | ICPT | INTERCEPT PHARMACE ... | Durso Jerome Benedict | Chief Operating Off ... | Payment of Exercise | F | 42.08 | 289 | 12,161 | 39,103 | 39.4 K to 39.1 K (-0.73 %) |
| Oct 05 2020 | ICPT | INTERCEPT PHARMACE ... | Kim Richard J | President US Comm & ... | Payment of Exercise | F | 42.08 | 223 | 9,384 | 20,828 | 21.1 K to 20.8 K (-1.06 %) |
| Sep 17 2020 | ICPT | INTERCEPT PHARMACE ... | Campagna Jason | Chief Medical Offic ... | Payment of Exercise | F | 43.41 | 69 | 2,995 | 8,709 | 8.8 K to 8.7 K (-0.79 %) |
| Aug 31 2020 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 48.81 | 357 | 17,425 | 16,380 | 16.7 K to 16.4 K (-2.13 %) |
| Aug 31 2020 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 48.81 | 357 | 17,425 | 16,380 | 16.7 K to 16.4 K (-2.13 %) |
| Aug 25 2020 | ICPT | INTERCEPT PHARMACE ... | Durso Jerome Benedict | Chief Operating Off ... | Payment of Exercise | F | 48.21 | 319 | 15,379 | 39,392 | 39.7 K to 39.4 K (-0.80 %) |
| Aug 20 2020 | ICPT | INTERCEPT PHARMACE ... | Campagna Jason | Chief Medical Offic ... | Sell | S | 47.44 | 1,192 | 56,543 | 8,778 | 10 K to 8.8 K (-11.96 %) |
| Aug 17 2020 | ICPT | INTERCEPT PHARMACE ... | Genextra S.p.A. | Sell | S | 46.75 | 1,235,512 | 57,760,186 | 4,000,000 | 5.2 M to 4 M (-23.60 %) | |
| Aug 17 2020 | ICPT | INTERCEPT PHARMACE ... | Genextra S.p.A. | Sell | S | 50.15 | 126,888 | 6,362,913 | 5,235,512 | 5.4 M to 5.2 M (-2.37 %) | |
| Aug 17 2020 | ICPT | INTERCEPT PHARMACE ... | Genextra S.p.A. | Sell | S | 50.55 | 54,600 | 2,760,112 | 5,362,400 | 5.4 M to 5.4 M (-1.01 %) | |
| Aug 17 2020 | ICPT | INTERCEPT PHARMACE ... | Genextra S.p.A. | Sell | S | 52.60 | 83,000 | 4,365,451 | 5,417,000 | 5.5 M to 5.4 M (-1.51 %) | |
| Aug 17 2020 | ICPT | INTERCEPT PHARMACE ... | Micheli Francesco | Sell | S | 46.75 | 1,235,512 | 57,760,186 | 4,000,000 | 5.2 M to 4 M (-23.60 %) | |
| Aug 17 2020 | ICPT | INTERCEPT PHARMACE ... | Micheli Francesco | Sell | S | 50.15 | 126,888 | 6,362,913 | 5,235,512 | 5.4 M to 5.2 M (-2.37 %) | |
| Aug 17 2020 | ICPT | INTERCEPT PHARMACE ... | Micheli Francesco | Sell | S | 50.55 | 54,600 | 2,760,112 | 5,362,400 | 5.4 M to 5.4 M (-1.01 %) | |
| Aug 17 2020 | ICPT | INTERCEPT PHARMACE ... | Micheli Francesco | Sell | S | 52.60 | 83,000 | 4,365,451 | 5,417,000 | 5.5 M to 5.4 M (-1.51 %) | |
| Aug 17 2020 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Sell | S | 46.75 | 1,235,512 | 57,760,186 | 4,000,000 | 5.2 M to 4 M (-23.60 %) | |
| Aug 17 2020 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Sell | S | 50.15 | 126,888 | 6,362,913 | 5,235,512 | 5.4 M to 5.2 M (-2.37 %) | |
| Aug 17 2020 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Sell | S | 50.55 | 54,600 | 2,760,112 | 5,362,400 | 5.4 M to 5.4 M (-1.01 %) | |
| Aug 17 2020 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Sell | S | 52.60 | 83,000 | 4,365,451 | 5,417,000 | 5.5 M to 5.4 M (-1.51 %) | |
| Aug 14 2020 | ICPT | INTERCEPT PHARMACE ... | Sullivan Ryan T | General Counsel and ... | Payment of Exercise | F | 51.86 | 493 | 25,567 | 25,201 | 25.7 K to 25.2 K (-1.92 %) |
| Aug 14 2020 | ICPT | INTERCEPT PHARMACE ... | Cawkwell Gail | SVP, Med Affairs, S ... | Payment of Exercise | F | 53.44 | 319 | 17,047 | 21,616 | 21.9 K to 21.6 K (-1.45 %) |
| Aug 11 2020 | ICPT | INTERCEPT PHARMACE ... | Ford David A | Chief Human Resourc ... | Payment of Exercise | F | 48.75 | 128 | 6,240 | 13,534 | 13.7 K to 13.5 K (-0.94 %) |
| Jul 06 2020 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 46.52 | 46 | 2,140 | 16,737 | 16.8 K to 16.7 K (-0.27 %) |
| Jul 06 2020 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President & CEO | Payment of Exercise | F | 46.52 | 772 | 35,913 | 476,289 | 477.1 K to 476.3 K (-0.16 %) |
| Jul 06 2020 | ICPT | INTERCEPT PHARMACE ... | Kim Richard J | President US Comm & ... | Payment of Exercise | F | 46.52 | 224 | 10,420 | 21,051 | 21.3 K to 21.1 K (-1.05 %) |
| Jul 06 2020 | ICPT | INTERCEPT PHARMACE ... | Kapadia Sandip | CFO and Treasurer | Payment of Exercise | F | 46.52 | 615 | 28,610 | 29,217 | 29.8 K to 29.2 K (-2.06 %) |
| Jul 06 2020 | ICPT | INTERCEPT PHARMACE ... | Ford David A | Chief Human Resourc ... | Payment of Exercise | F | 46.52 | 92 | 4,280 | 13,662 | 13.8 K to 13.7 K (-0.67 %) |
| Jul 06 2020 | ICPT | INTERCEPT PHARMACE ... | Campagna Jason | Chief Medical Offic ... | Payment of Exercise | F | 46.52 | 112 | 5,210 | 9,970 | 10.1 K to 10 K (-1.11 %) |
| Jul 06 2020 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President, Internat ... | Payment of Exercise | F | 46.52 | 301 | 14,003 | 22,012 | 22.3 K to 22 K (-1.35 %) |
| Jul 06 2020 | ICPT | INTERCEPT PHARMACE ... | Durso Jerome Benedict | Chief Operating Off ... | Payment of Exercise | F | 46.52 | 289 | 13,444 | 39,711 | 40 K to 39.7 K (-0.72 %) |
| Jun 17 2020 | ICPT | INTERCEPT PHARMACE ... | Campagna Jason | Chief Medical Offic ... | Payment of Exercise | F | 77.40 | 70 | 5,418 | 10,082 | 10.2 K to 10.1 K (-0.69 %) |
| Jun 01 2020 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Option Exercise | A | 72.74 | 2,966 | 215,747 | 2,966 | |
| Jun 01 2020 | ICPT | INTERCEPT PHARMACE ... | AKKARAJU SRINIVAS | Director | Grant | A | 0.00 | 1,595 | 0 | 23,121 | 21.5 K to 23.1 K (+7.41 %) |
| Jun 01 2020 | ICPT | INTERCEPT PHARMACE ... | Benatti Luca | Director | Option Exercise | A | 72.74 | 2,966 | 215,747 | 2,966 | |
| Jun 01 2020 | ICPT | INTERCEPT PHARMACE ... | Benatti Luca | Director | Grant | A | 0.00 | 1,595 | 0 | 10,721 | 9.1 K to 10.7 K (+17.48 %) |
| Jun 01 2020 | ICPT | INTERCEPT PHARMACE ... | BRADBURY DANIEL | Director | Option Exercise | A | 72.74 | 2,966 | 215,747 | 2,966 | |
| Jun 01 2020 | ICPT | INTERCEPT PHARMACE ... | BRADBURY DANIEL | Director | Grant | A | 0.00 | 1,595 | 0 | 8,782 | 7.2 K to 8.8 K (+22.19 %) |
| Jun 01 2020 | ICPT | INTERCEPT PHARMACE ... | Gottesdiener Keith Michael | Director | Option Exercise | A | 72.74 | 2,966 | 215,747 | 2,966 | |
| Jun 01 2020 | ICPT | INTERCEPT PHARMACE ... | Gottesdiener Keith Michael | Director | Grant | A | 0.00 | 1,595 | 0 | 9,953 | 8.4 K to 10 K (+19.08 %) |
| Jun 01 2020 | ICPT | INTERCEPT PHARMACE ... | Miller-Rich Nancy | Director | Option Exercise | A | 72.74 | 2,966 | 215,747 | 2,966 | |
| Jun 01 2020 | ICPT | INTERCEPT PHARMACE ... | Miller-Rich Nancy | Director | Grant | A | 0.00 | 1,595 | 0 | 7,538 | 5.9 K to 7.5 K (+26.84 %) |
| Jun 01 2020 | ICPT | INTERCEPT PHARMACE ... | SANTINI GINO | Director | Option Exercise | A | 72.74 | 2,966 | 215,747 | 2,966 | |
| Jun 01 2020 | ICPT | INTERCEPT PHARMACE ... | SANTINI GINO | Director | Grant | A | 0.00 | 1,595 | 0 | 8,879 | 7.3 K to 8.9 K (+21.90 %) |
| Jun 01 2020 | ICPT | INTERCEPT PHARMACE ... | SBLENDORIO GLENN | Director | Option Exercise | A | 72.74 | 2,966 | 215,747 | 2,966 | |
| Jun 01 2020 | ICPT | INTERCEPT PHARMACE ... | SBLENDORIO GLENN | Director | Grant | A | 0.00 | 1,595 | 0 | 8,681 | 7.1 K to 8.7 K (+22.51 %) |
| Jun 01 2020 | ICPT | INTERCEPT PHARMACE ... | WELCH DANIEL G | Director | Option Exercise | A | 72.74 | 2,966 | 215,747 | 2,966 | |
| Jun 01 2020 | ICPT | INTERCEPT PHARMACE ... | WELCH DANIEL G | Director | Grant | A | 0.00 | 1,595 | 0 | 8,060 | 6.5 K to 8.1 K (+24.67 %) |
| Jun 01 2020 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Option Exercise | A | 72.74 | 2,966 | 215,747 | 2,966 | |
| Jun 01 2020 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Grant | A | 0.00 | 1,595 | 0 | 21,028 | 19.4 K to 21 K (+8.21 %) |
| May 29 2020 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 74.43 | 357 | 26,572 | 16,783 | 17.1 K to 16.8 K (-2.08 %) |
| May 27 2020 | ICPT | INTERCEPT PHARMACE ... | Durso Jerome Benedict | Chief Operating Off ... | Payment of Exercise | F | 80.51 | 319 | 25,683 | 40,000 | 40.3 K to 40 K (-0.79 %) |
| May 15 2020 | ICPT | INTERCEPT PHARMACE ... | Fundaro Paolo | Director | Sell | S | 84.60 | 595,578 | 50,385,899 | 5,500,000 | 6.1 M to 5.5 M (-9.77 %) |
| May 15 2020 | ICPT | INTERCEPT PHARMACE ... | Micheli Francesco | 10% Owner | Sell | S | 84.60 | 595,578 | 50,385,899 | 5,500,000 | 6.1 M to 5.5 M (-9.77 %) |
| May 15 2020 | ICPT | INTERCEPT PHARMACE ... | Genextra S.p.A. | 10% Owner | Sell | S | 84.60 | 595,578 | 50,385,899 | 5,500,000 | 6.1 M to 5.5 M (-9.77 %) |
| May 15 2020 | ICPT | INTERCEPT PHARMACE ... | Genextra S.p.A. | 10% Owner | Sell | S | 84.60 | 595,578 | 50,385,899 | 5,500,000 | 6.1 M to 5.5 M (-9.77 %) |
| May 14 2020 | ICPT | INTERCEPT PHARMACE ... | Sullivan Ryan T | General Counsel and ... | Payment of Exercise | F | 85.08 | 493 | 41,944 | 25,694 | 26.2 K to 25.7 K (-1.88 %) |
| May 14 2020 | ICPT | INTERCEPT PHARMACE ... | Cawkwell Gail | SVP, Med Affairs, S ... | Payment of Exercise | F | 89.05 | 319 | 28,407 | 21,935 | 22.3 K to 21.9 K (-1.43 %) |
| May 12 2020 | ICPT | INTERCEPT PHARMACE ... | Ford David A | Chief Human Resourc ... | Payment of Exercise | F | 87.80 | 128 | 11,238 | 13,754 | 13.9 K to 13.8 K (-0.92 %) |
| Apr 29 2020 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Sell | S | 85.95 | 181 | 15,557 | 17,140 | 17.3 K to 17.1 K (-1.04 %) |
| Apr 10 2020 | ICPT | INTERCEPT PHARMACE ... | Ford David A | Chief Human Resourc ... | Sell | S | 70.00 | 58 | 4,060 | 13,882 | 13.9 K to 13.9 K (-0.42 %) |
| Apr 10 2020 | ICPT | INTERCEPT PHARMACE ... | Ford David A | Chief Human Resourc ... | Sell | S | 70.00 | 58 | 4,060 | 13,882 | 13.9 K to 13.9 K (-0.42 %) |
| Apr 03 2020 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 58.40 | 46 | 2,686 | 17,321 | 17.4 K to 17.3 K (-0.26 %) |
| Apr 03 2020 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President & CEO | Payment of Exercise | F | 58.40 | 568 | 33,171 | 477,061 | 477.6 K to 477.1 K (-0.12 %) |
| Apr 03 2020 | ICPT | INTERCEPT PHARMACE ... | Kim Richard J | President US Comm & ... | Payment of Exercise | F | 58.40 | 223 | 13,023 | 21,275 | 21.5 K to 21.3 K (-1.04 %) |
| Apr 03 2020 | ICPT | INTERCEPT PHARMACE ... | Kapadia Sandip | CFO and Treasurer | Payment of Exercise | F | 58.40 | 615 | 35,916 | 29,832 | 30.4 K to 29.8 K (-2.02 %) |
| Apr 03 2020 | ICPT | INTERCEPT PHARMACE ... | Ford David A | Chief Human Resourc ... | Payment of Exercise | F | 58.40 | 92 | 5,373 | 13,940 | 14 K to 13.9 K (-0.66 %) |
| Apr 03 2020 | ICPT | INTERCEPT PHARMACE ... | Durso Jerome Benedict | Chief Operating Off ... | Payment of Exercise | F | 58.40 | 289 | 16,878 | 40,319 | 40.6 K to 40.3 K (-0.71 %) |
| Apr 03 2020 | ICPT | INTERCEPT PHARMACE ... | Campagna Jason | Chief Medical Offic ... | Payment of Exercise | F | 58.40 | 112 | 6,541 | 10,152 | 10.3 K to 10.2 K (-1.09 %) |
| Apr 03 2020 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President, Internat ... | Payment of Exercise | F | 58.40 | 301 | 17,578 | 22,313 | 22.6 K to 22.3 K (-1.33 %) |
| Mar 17 2020 | ICPT | INTERCEPT PHARMACE ... | Campagna Jason | Chief Medical Offic ... | Payment of Exercise | F | 71.82 | 69 | 4,956 | 10,264 | 10.3 K to 10.3 K (-0.67 %) |
| Feb 28 2020 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Sell | S | 87.62 | 113 | 9,901 | 17,367 | 17.5 K to 17.4 K (-0.65 %) |
| Feb 28 2020 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Payment of Exercise | F | 85.39 | 357 | 30,484 | 17,480 | 17.8 K to 17.5 K (-2.00 %) |
| Feb 24 2020 | ICPT | INTERCEPT PHARMACE ... | Durso Jerome Benedict | Chief Operating Off ... | Payment of Exercise | F | 94.99 | 319 | 30,302 | 40,608 | 40.9 K to 40.6 K (-0.78 %) |
| Feb 21 2020 | ICPT | INTERCEPT PHARMACE ... | Campagna Jason | Chief Medical Offic ... | Payment of Exercise | F | 96.24 | 170 | 16,361 | 10,333 | 10.5 K to 10.3 K (-1.62 %) |
| Feb 14 2020 | ICPT | INTERCEPT PHARMACE ... | Sullivan Ryan T | General Counsel and ... | Payment of Exercise | F | 94.69 | 493 | 46,682 | 26,187 | 26.7 K to 26.2 K (-1.85 %) |
| Feb 14 2020 | ICPT | INTERCEPT PHARMACE ... | Cawkwell Gail | SVP, Med Affairs, S ... | Payment of Exercise | F | 96.74 | 319 | 30,860 | 22,254 | 22.6 K to 22.3 K (-1.41 %) |
| Feb 11 2020 | ICPT | INTERCEPT PHARMACE ... | Ford David A | Chief Human Resourc ... | Payment of Exercise | F | 95.17 | 148 | 14,085 | 14,032 | 14.2 K to 14 K (-1.04 %) |
| Jan 27 2020 | ICPT | INTERCEPT PHARMACE ... | Kim Richard J | President US Comm & ... | Option Exercise | A | 99.66 | 8,800 | 877,008 | 8,800 | |
| Jan 27 2020 | ICPT | INTERCEPT PHARMACE ... | Kim Richard J | President US Comm & ... | Grant | A | 0.00 | 5,400 | 0 | 21,498 | 16.1 K to 21.5 K (+33.54 %) |
| Jan 27 2020 | ICPT | INTERCEPT PHARMACE ... | Kapadia Sandip | CFO and Treasurer | Option Exercise | A | 99.66 | 9,200 | 916,872 | 9,200 | |
| Jan 27 2020 | ICPT | INTERCEPT PHARMACE ... | Kapadia Sandip | CFO and Treasurer | Grant | A | 0.00 | 5,600 | 0 | 30,447 | 24.8 K to 30.4 K (+22.54 %) |
| Jan 27 2020 | ICPT | INTERCEPT PHARMACE ... | Ford David A | Chief Human Resourc ... | Option Exercise | A | 99.66 | 5,900 | 587,994 | 5,900 | |
| Jan 27 2020 | ICPT | INTERCEPT PHARMACE ... | Ford David A | Chief Human Resourc ... | Grant | A | 0.00 | 3,600 | 0 | 14,180 | 10.6 K to 14.2 K (+34.03 %) |
| Jan 27 2020 | ICPT | INTERCEPT PHARMACE ... | Durso Jerome Benedict | Chief Operating Off ... | Option Exercise | A | 99.66 | 17,400 | 1,734,084 | 17,400 | |
| Jan 27 2020 | ICPT | INTERCEPT PHARMACE ... | Durso Jerome Benedict | Chief Operating Off ... | Grant | A | 0.00 | 10,600 | 0 | 40,927 | 30.3 K to 40.9 K (+34.95 %) |
| Jan 27 2020 | ICPT | INTERCEPT PHARMACE ... | Cawkwell Gail | SVP, Med Affairs, S ... | Option Exercise | A | 99.66 | 6,900 | 687,654 | 6,900 | |
| Jan 27 2020 | ICPT | INTERCEPT PHARMACE ... | Cawkwell Gail | SVP, Med Affairs, S ... | Grant | A | 0.00 | 4,200 | 0 | 22,573 | 18.4 K to 22.6 K (+22.86 %) |
| Jan 27 2020 | ICPT | INTERCEPT PHARMACE ... | Campagna Jason | Chief Medical Offic ... | Option Exercise | A | 99.66 | 6,900 | 687,654 | 6,900 | |
| Jan 27 2020 | ICPT | INTERCEPT PHARMACE ... | Campagna Jason | Chief Medical Offic ... | Grant | A | 0.00 | 4,200 | 0 | 10,503 | 6.3 K to 10.5 K (+66.63 %) |
| Jan 27 2020 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President, Internat ... | Option Exercise | A | 99.66 | 7,900 | 787,314 | 7,900 | |
| Jan 27 2020 | ICPT | INTERCEPT PHARMACE ... | Bright Lisa | President, Internat ... | Grant | A | 0.00 | 4,800 | 0 | 22,614 | 17.8 K to 22.6 K (+26.95 %) |
| Jan 27 2020 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Option Exercise | A | 99.66 | 7,900 | 787,314 | 7,900 | |
| Jan 27 2020 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Sell | S | 94.04 | 723 | 67,991 | 17,837 | 18.6 K to 17.8 K (-3.90 %) |
| Jan 27 2020 | ICPT | INTERCEPT PHARMACE ... | Weyer Christian | EVP, Research & Dev ... | Grant | A | 0.00 | 4,800 | 0 | 18,560 | 13.8 K to 18.6 K (+34.88 %) |
| Jan 27 2020 | ICPT | INTERCEPT PHARMACE ... | Sullivan Ryan T | General Counsel and ... | Option Exercise | A | 99.66 | 9,200 | 916,872 | 9,200 | |
| Jan 27 2020 | ICPT | INTERCEPT PHARMACE ... | Sullivan Ryan T | General Counsel and ... | Grant | A | 0.00 | 5,600 | 0 | 26,680 | 21.1 K to 26.7 K (+26.57 %) |
| Jan 27 2020 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President & CEO | Option Exercise | A | 99.66 | 17,700 | 1,763,982 | 17,700 | |
| Jan 27 2020 | ICPT | INTERCEPT PHARMACE ... | Pruzanski Mark | President & CEO | Grant | A | 0.00 | 10,800 | 0 | 477,629 | 466.8 K to 477.6 K (+2.31 %) |
| Jan 08 2020 | ICPT | INTERCEPT PHARMACE ... | Campagna Jason | Chief Medical Offic ... | Sell | S | 113.02 | 732 | 82,731 | 6,303 | 7 K to 6.3 K (-10.41 %) |
| Jan 03 2020 | ICPT | INTERCEPT PHARMACE ... | Durso Jerome Benedict | Chief Operating Off ... | Payment of Exercise | F | 123.92 | 334 | 41,389 | 30,327 | 30.7 K to 30.3 K (-1.09 %) |
| Jan 03 2020 | ICPT | INTERCEPT PHARMACE ... | Durso Jerome Benedict | Chief Operating Off ... | Payment of Exercise | F | 123.92 | 1,151 | 142,632 | 30,661 | 31.8 K to 30.7 K (-3.62 %) |
| Jan 03 2020 | ICPT | INTERCEPT PHARMACE ... | Kim Richard J | President US Comm & ... | Payment of Exercise | F | 123.92 | 309 | 38,291 | 16,098 | 16.4 K to 16.1 K (-1.88 %) |
| Jan 03 2020 | ICPT | INTERCEPT PHARMACE ... | Kim Richard J | President US Comm & ... | Payment of Exercise | F | 123.92 | 340 | 42,133 | 16,407 | 16.7 K to 16.4 K (-2.03 %) |
| Jan 03 2020 | ICPT | INTERCEPT PHARMACE ... | Kapadia Sandip | CFO and Treasurer | Payment of Exercise | F | 123.92 | 669 | 82,902 | 24,847 | 25.5 K to 24.8 K (-2.62 %) |
| Jan 03 2020 | ICPT | INTERCEPT PHARMACE ... | Kapadia Sandip | CFO and Treasurer | Payment of Exercise | F | 123.92 | 551 | 68,280 | 25,516 | 26.1 K to 25.5 K (-2.11 %) |